Market Overview: The Australian market is facing volatility, with ASX 200 futures indicating a significant drop due to economic uncertainties, while penny stocks remain attractive to investors for their growth potential.
Highlighted Penny Stocks: Notable penny stocks on the ASX include Alfabs Australia, Dusk Group, and IVE Group, which are recognized for their financial health and growth prospects amidst current market conditions.
Immutep Limited: This biotechnology company, focused on immunotherapies for cancer, has a market cap of A$404.78 million and is showing promising clinical trial results despite being pre-revenue.
Omni Bridgeway Limited: With a market cap of A$449.96 million, this company has transitioned to profitability, reporting significant revenue and strong liquidity, while Propel Funeral Partners Limited operates in the death care sector with stable financial performance.
Wall Street analysts forecast IMMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMP is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IMMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMP is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.940
Low
12.00
Averages
12.00
High
12.00
Current: 2.940
Low
12.00
Averages
12.00
High
12.00
No data
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
